<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35204685</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2218-273X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biomolecules</Title>
          <ISOAbbreviation>Biomolecules</ISOAbbreviation>
        </Journal>
        <ArticleTitle>CNS-Sparing Histamine H<sub>3</sub> Receptor Antagonist as a Candidate to Prevent the Diabetes-Associated Gastrointestinal Symptoms.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">184</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/biom12020184</ELocationID>
        <Abstract>
          <AbstractText>Among the histamine receptors, growing evidence points to the histamine H<sub>3</sub> receptor as a pharmacological candidate to counteract the autonomic neuropathy associated with diabetes. The study aimed to evaluate the effect of PF00868087 (also known as ZPL-868), a CNS-sparing histamine H<sub>3</sub> receptor antagonist, on the autonomic neuropathy of the intestinal tract associated with diabetes. Diabetes was induced in male BALB/c mice by a single high dose of streptozotocin (150 mg/kg). Colorectal specimens from control and diabetic mice, randomized to vehicle or PF0086087 (10, 30, 100 mg/kg/day by oral gavage for 14 days), were processed for morphological and immunohistochemical analysis. A significant overproduction of mucus in the intestinal mucosa of diabetic mice compared to the controls was observed. PF0086087 at the highest dose prevented mucin overproduction. The immunohistochemistry analysis demonstrated that diabetes causes a decrease in the inhibitory component of enteric motility, measured as the percentage of neuronal nitric oxide synthase-positive neurons (<i>p</i> &lt; 0.05) and a parallel increase in the excitatory component evaluated as substance P-positive fibres (<i>p</i> &lt; 0.01). PF0086087 dose-dependently prevented these pathophysiological events. In conclusion, PF0086087 may be an essential tool in preventing nitrergic dysfunction in the myenteric plexus of the distal colon and diabetes-induced gastrointestinal complications.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rosa</LastName>
            <ForeName>Arianna Carolina</ForeName>
            <Initials>AC</Initials>
            <Identifier Source="ORCID">0000-0002-6139-9241</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Scienza e Tecnologia del Farmaco, University of Turin, Via P. Giuria 9, 10125 Turin, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nardini</LastName>
            <ForeName>Patrizia</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0003-2374-5147</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sgambellone</LastName>
            <ForeName>Silvia</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-5143-9959</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Pharmacology and Toxicology Section, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gurrieri</LastName>
            <ForeName>Maura</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Spampinato</LastName>
            <ForeName>Simona Federica</ForeName>
            <Initials>SF</Initials>
            <Identifier Source="ORCID">0000-0001-7564-1986</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Scienza e Tecnologia del Farmaco, University of Turin, Via P. Giuria 9, 10125 Turin, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dell'Accio</LastName>
            <ForeName>Alfonso</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-6674-8781</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chazot</LastName>
            <ForeName>Paul L</ForeName>
            <Initials>PL</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biological and Biomedical Science, Durham University, Durham DH1 3LE, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Obara</LastName>
            <ForeName>Ilona</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy and Translational and Clinical Research Institute, King George VI Building, Newcastle University, Newcastle-upon-Tyne NE1 7RU, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Wai L</ForeName>
            <Initials>WL</Initials>
            <AffiliationInfo>
              <Affiliation>Liu &amp; Co Consulting Limited, Whitstable CT5 3RF, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pini</LastName>
            <ForeName>Alessandro</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-9828-2082</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical and Experimental Medicine, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Biomolecules</MedlineTA>
        <NlmUniqueID>101596414</NlmUniqueID>
        <ISSNLinking>2218-273X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006633">Histamine Antagonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5W494URQ81</RegistryNumber>
          <NameOfSubstance UI="D013311">Streptozocin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003921" MajorTopicYN="Y">Diabetes Mellitus, Experimental</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005767" MajorTopicYN="Y">Gastrointestinal Diseases</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006633" MajorTopicYN="N">Histamine Antagonists</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009197" MajorTopicYN="N">Myenteric Plexus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013311" MajorTopicYN="N">Streptozocin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">PF0086087</Keyword>
        <Keyword MajorTopicYN="Y">ZPL-868</Keyword>
        <Keyword MajorTopicYN="Y">diabetes</Keyword>
        <Keyword MajorTopicYN="Y">gastrointestinal neuropathy</Keyword>
        <Keyword MajorTopicYN="Y">histamine</Keyword>
      </KeywordList>
      <CoiStatement>W.L.L., through a Material Transfer Agreement, provided PF00868087 used in the experiments. The rest of authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>1</Hour>
          <Minute>4</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35204685</ArticleId>
        <ArticleId IdType="pmc">PMC8961615</ArticleId>
        <ArticleId IdType="doi">10.3390/biom12020184</ArticleId>
        <ArticleId IdType="pii">biom12020184</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kuznik E., Dudkowiak R., Adamiec R., Poniewierka E. Diabetic autonomic neuropathy of the gastrointestinal tract. Prz. Gastroenterol. 2020;15:89–93. doi: 10.5114/pg.2020.95554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/pg.2020.95554</ArticleId>
            <ArticleId IdType="pmc">PMC7294968</ArticleId>
            <ArticleId IdType="pubmed">32550939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pini A., Obara I., Battell E., Chazot P.L., Rosa A.C. Histamine in diabetes: Is it time to reconsider? Pharmacol. Res. 2016;111:316–324. doi: 10.1016/j.phrs.2016.06.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phrs.2016.06.021</ArticleId>
            <ArticleId IdType="pubmed">27343700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azpiroz F., Malagelada C. Diabetic neuropathy in the gut: Pathogenesis and diagnosis. Diabetologia. 2016;59:404–408. doi: 10.1007/s00125-015-3831-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00125-015-3831-1</ArticleId>
            <ArticleId IdType="pubmed">26643877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Shboul O.A. The importance of interstitial cells of cajal in the gastrointestinal tract. Saudi. J. Gastroenterol. 2013;19:3–15. doi: 10.4103/1319-3767.105909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/1319-3767.105909</ArticleId>
            <ArticleId IdType="pmc">PMC3603487</ArticleId>
            <ArticleId IdType="pubmed">23319032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sick E., Brehin S., Andre P., Coupin G., Landry Y., Takeda K., Gies J.P. Advanced glycation end products (AGEs) activate mast cells. Br. J. Pharmacol. 2010;161:442–455. doi: 10.1111/j.1476-5381.2010.00905.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1476-5381.2010.00905.x</ArticleId>
            <ArticleId IdType="pmc">PMC2989594</ArticleId>
            <ArticleId IdType="pubmed">20735427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosa A.C., Fantozzi R. The role of histamine in neurogenic inflammation. Br. J. Pharmacol. 2013;170:38–45. doi: 10.1111/bph.12266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.12266</ArticleId>
            <ArticleId IdType="pmc">PMC3764847</ArticleId>
            <ArticleId IdType="pubmed">23734637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atencio A.S.M., de Manzo F.A.P., Velasco M. Role of Histamine as a Peripheral Sympathetic Neuromediator and its Interrelation with Substance P. Curr. Pharm. Des. 2020;26:4486–4495. doi: 10.2174/1381612826666200813132951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1381612826666200813132951</ArticleId>
            <ArticleId IdType="pubmed">32787755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lovenberg T.W., Roland B.L., Wilson S.J., Jiang X., Pyati J., Huvar A., Jackson M.R., Erlander M.G. Cloning and functional expression of the human histamine H3 receptor. Mol. Pharmacol. 1999;55:1101–1107. doi: 10.1124/mol.55.6.1101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.55.6.1101</ArticleId>
            <ArticleId IdType="pubmed">10347254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grandi D., Shenton F.C., Chazot P.L., Morini G. Immunolocalization of histamine H3 receptors on endocrine cells in the rat gastrointestinal tract. Histol. Histopathol. 2008;23:789–798. doi: 10.14670/HH-23.789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14670/HH-23.789</ArticleId>
            <ArticleId IdType="pubmed">18437677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chazot P., Shenton F., Schunack W., Grandi D., Morini G. Influence of (R)-alpha-methylhistamine on the histamine H3 receptor in the rat gastrointestinal tract. Inflamm. Res. 2007;56((Suppl. S1)):S19–S20. doi: 10.1007/s00011-006-0509-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00011-006-0509-7</ArticleId>
            <ArticleId IdType="pubmed">17806162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morini G., Becchi G., Shenton F.C., Chazot P.L., Grandi D. Histamine H3 and H4 receptors are expressed on distinct endocrine cell types in the rat fundic mucosa. Inflamm. Res. 2008;57((Suppl. S1)):S57–S58. doi: 10.1007/s00011-007-0628-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00011-007-0628-9</ArticleId>
            <ArticleId IdType="pubmed">18345490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obara I., Telezhkin V., Alrashdi I., Chazot P.L. Histamine, histamine receptors, and neuropathic pain relief. Br. J. Pharmacol. 2020;177:580–599. doi: 10.1111/bph.14696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.14696</ArticleId>
            <ArticleId IdType="pmc">PMC7012972</ArticleId>
            <ArticleId IdType="pubmed">31046146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arrang J.M., Garbarg M., Schwartz J.C. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature. 1983;302:832–837. doi: 10.1038/302832a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/302832a0</ArticleId>
            <ArticleId IdType="pubmed">6188956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hough L.B., Rice F.L. H3 receptors and pain modulation: Peripheral, spinal, and brain interactions. J. Pharmacol. Exp. Ther. 2011;336:30–37. doi: 10.1124/jpet.110.171264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/jpet.110.171264</ArticleId>
            <ArticleId IdType="pmc">PMC3014298</ArticleId>
            <ArticleId IdType="pubmed">20864501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silver R.B., Mackins C.J., Smith N.C., Koritchneva I.L., Lefkowitz K., Lovenberg T.W., Levi R. Coupling of histamine H3 receptors to neuronal Na+/H+ exchange: A novel protective mechanism in myocardial ischemia. Proc. Natl. Acad. Sci. USA. 2001;98:2855–2859. doi: 10.1073/pnas.051599198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.051599198</ArticleId>
            <ArticleId IdType="pmc">PMC30229</ArticleId>
            <ArticleId IdType="pubmed">11226330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erfanparast A., Tamaddonfard E., Farshid A.A., Khalilzadeh E. Effect of microinjection of histamine into the dorsal hippocampus on the orofacial formalin-induced pain in rats. Eur. J. Pharmacol. 2010;627:119–123. doi: 10.1016/j.ejphar.2009.10.063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2009.10.063</ArticleId>
            <ArticleId IdType="pubmed">19891965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamaddonfard E., Hamzeh-Gooshchi N. Effects of administration of histamine and its H1, H2, and H3 receptor antagonists into the primary somatosensory cortex on inflammatory pain in rats. Iran. J. Basic Med. Sci. 2014;17:55–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3938887</ArticleId>
            <ArticleId IdType="pubmed">24592308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khalilzadeh E., Azarpey F., Hazrati R., Vafaei Saiah G. Evaluation of different classes of histamine H1 and H2 receptor antagonist effects on neuropathic nociceptive behavior following tibial nerve transection in rats. Eur. J. Pharmacol. 2018;834:221–229. doi: 10.1016/j.ejphar.2018.07.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2018.07.011</ArticleId>
            <ArticleId IdType="pubmed">30009812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshimoto R., Miyamoto Y., Shimamura K., Ishihara A., Takahashi K., Kotani H., Chen A.S., Chen H.Y., Macneil D.J., Kanatani A., et al.  Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc. Natl. Acad. Sci. USA. 2006;103:13866–13871. doi: 10.1073/pnas.0506104103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0506104103</ArticleId>
            <ArticleId IdType="pmc">PMC1560086</ArticleId>
            <ArticleId IdType="pubmed">16954192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henry M.B., Zheng S., Duan C., Patel B., Vassileva G., Sondey C., Lachowicz J., Hwa J.J. Antidiabetic properties of the histamine H3 receptor protean agonist proxyfan. Endocrinology. 2011;152:828–835. doi: 10.1210/en.2010-0757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/en.2010-0757</ArticleId>
            <ArticleId IdType="pubmed">21239440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotanska M., Kuder K.J., Szczepanska K., Sapa J., Kiec-Kononowicz K. The histamine H3 receptor inverse agonist pitolisant reduces body weight in obese mice. Naunyn. Schmiedebergs Arch. Pharmacol. 2018;391:875–881. doi: 10.1007/s00210-018-1516-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00210-018-1516-2</ArticleId>
            <ArticleId IdType="pmc">PMC6061715</ArticleId>
            <ArticleId IdType="pubmed">29802412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tokita S., Takahashi K., Kotani H. Recent advances in molecular pharmacology of the histamine systems: Physiology and pharmacology of histamine H3 receptor: Roles in feeding regulation and therapeutic potential for metabolic disorders. J. Pharmacol. Sci. 2006;101:12–18. doi: 10.1254/jphs.FMJ06001X4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1254/jphs.FMJ06001X4</ArticleId>
            <ArticleId IdType="pubmed">16648667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao A.U., Shao N., Aslanian R.G., Chan T.Y., Degrado S.J., Wang L., McKittrick B., Senior M., West R.E., Jr., Williams S.M., et al.  Discovery of a potent thiadiazole class of histamine h3 receptor antagonist for the treatment of diabetes. ACS Med. Chem. Lett. 2012;3:198–202. doi: 10.1021/ml200250t.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ml200250t</ArticleId>
            <ArticleId IdType="pmc">PMC4025655</ArticleId>
            <ArticleId IdType="pubmed">24900450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lunn G., Mowbray C.E., Liu W.L.S., Joynson V.M., Hayc T., Yeadonb M. The discovery and profile of PF-0868087, a CNS-sparing histamine H3 receptor antagonist for the treatment of allergic rhinitis. Med. Chem. Commun. 2012;3:339–343. doi: 10.1039/C2MD00276K.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C2MD00276K</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Brien P.D., Sakowski S.A., Feldman E.L. Mouse models of diabetic neuropathy. ILAR J. 2014;54:259–272. doi: 10.1093/ilar/ilt052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ilar/ilt052</ArticleId>
            <ArticleId IdType="pmc">PMC3962259</ArticleId>
            <ArticleId IdType="pubmed">24615439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X., Lin S., Yang Y., Gong X., Tong J., Li K., Li Y. Histological and ultrastructural changes of the colon in dextran sodium sulfate-induced mouse colitis. Exp. Ther. Med. 2020;20:1987–1994. doi: 10.3892/etm.2020.8946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/etm.2020.8946</ArticleId>
            <ArticleId IdType="pmc">PMC7401218</ArticleId>
            <ArticleId IdType="pubmed">32782508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Diest S.A., Stanisor O.I., Boeckxstaens G.E., de Jonge W.J., van den Wijngaard R.M. Relevance of mast cell-nerve interactions in intestinal nociception. Biochim. Biophys. Acta. 2012;1822:74–84. doi: 10.1016/j.bbadis.2011.03.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2011.03.019</ArticleId>
            <ArticleId IdType="pubmed">21496484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furness J.B., Callaghan B.P., Rivera L.R., Cho H.J. The enteric nervous system and gastrointestinal innervation: Integrated local and central control. Adv. Exp. Med. Biol. 2014;817:39–71. doi: 10.1007/978-1-4939-0897-4_3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-0897-4_3</ArticleId>
            <ArticleId IdType="pubmed">24997029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meldgaard T., Olesen S.S., Farmer A.D., Krogh K., Wendel A.A., Brock B., Drewes A.M., Brock C. Diabetic Enteropathy: From Molecule to Mechanism-Based Treatment. J. Diabetes Res. 2018;2018:3827301. doi: 10.1155/2018/3827301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2018/3827301</ArticleId>
            <ArticleId IdType="pmc">PMC6165592</ArticleId>
            <ArticleId IdType="pubmed">30306092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schemann M., Michel K., Ceregrzyn M., Zeller F., Seidl S., Bischoff S.C. Human mast cell mediator cocktail excites neurons in human and guinea-pig enteric nervous system. Neurogastroenterol. Motil. 2005;17:281–289. doi: 10.1111/j.1365-2982.2004.00591.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2982.2004.00591.x</ArticleId>
            <ArticleId IdType="pubmed">15787948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sander L.E., Lorentz A., Sellge G., Coeffier M., Neipp M., Veres T., Frieling T., Meier P.N., Manns M.P., Bischoff S.C. Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract. Gut. 2006;55:498–504. doi: 10.1136/gut.2004.061762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2004.061762</ArticleId>
            <ArticleId IdType="pmc">PMC1856162</ArticleId>
            <ArticleId IdType="pubmed">16299042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breunig E., Michel K., Zeller F., Seidl S., Weyhern C.W., Schemann M. Histamine excites neurones in the human submucous plexus through activation of H1, H2, H3 and H4 receptors. J. Physiol. 2007;583:731–742. doi: 10.1113/jphysiol.2007.139352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/jphysiol.2007.139352</ArticleId>
            <ArticleId IdType="pmc">PMC2277025</ArticleId>
            <ArticleId IdType="pubmed">17627982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J., Yan L.J. Streptozotocin-induced type 1 diabetes in rodents as a model for studying mitochondrial mechanisms of diabetic beta cell glucotoxicity. Diabetes Metab. Syndr. Obes. 2015;8:181–188. doi: 10.2147/DMSO.S82272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/DMSO.S82272</ArticleId>
            <ArticleId IdType="pmc">PMC4396517</ArticleId>
            <ArticleId IdType="pubmed">25897251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gill D.S., Thompson C.S., Dandona P. Increased histamine in plasma and tissues in diabetic rats. Diabetes Res. 1988;7:31–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3402164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gill D.S., Thompson C.S., Dandona P. Histamine synthesis and catabolism in various tissues in diabetic rats. Metabolism. 1990;39:815–818. doi: 10.1016/0026-0495(90)90124-U.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0026-0495(90)90124-U</ArticleId>
            <ArticleId IdType="pubmed">2377078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fogel W.A., Chmielecki C., Gralek M., Maslinski C. Histamine metabolism in diabetic rats. Agents Actions. 1990;30:243–246. doi: 10.1007/BF01969050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01969050</ArticleId>
            <ArticleId IdType="pubmed">2115241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semra Y.K., Wang M., Peat N.J., Smith N.C., Shotton H.R., Lincoln J. Selective susceptibility of different populations of sympathetic neurons to diabetic neuropathy in vivo is reflected by increased vulnerability to oxidative stress in vitro. Neurosci. Lett. 2006;407:199–204. doi: 10.1016/j.neulet.2006.08.045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neulet.2006.08.045</ArticleId>
            <ArticleId IdType="pubmed">16973273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantle M., Thakore E., Mathison R., Davison J.S. Intestinal mucin secretion in streptozotocin-diabetic rats: Lack of response to cholinergic stimulation and cholera toxin. Dig. Dis. Sci. 1991;36:1574–1581. doi: 10.1007/BF01296400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01296400</ArticleId>
            <ArticleId IdType="pubmed">1682117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Domenech A., Pasquinelli G., De Giorgio R., Gori A., Bosch F., Pumarola M., Jimenez M. Morphofunctional changes underlying intestinal dysmotility in diabetic RIP-I/hIFNbeta transgenic mice. Int. J. Exp. Pathol. 2011;92:400–412. doi: 10.1111/j.1365-2613.2011.00789.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2613.2011.00789.x</ArticleId>
            <ArticleId IdType="pmc">PMC3248076</ArticleId>
            <ArticleId IdType="pubmed">22050417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanormelingen C., Tack J., Andrews C.N. Diabetic gastroparesis. Br. Med. Bull. 2013;105:213–230. doi: 10.1093/bmb/ldt003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bmb/ldt003</ArticleId>
            <ArticleId IdType="pubmed">23363458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonkowski S. Substance P as a neuronal factor in the enteric nervous system of the porcine descending colon in physiological conditions and during selected pathogenic processes. Biofactors. 2013;39:542–551. doi: 10.1002/biof.1097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/biof.1097</ArticleId>
            <ArticleId IdType="pubmed">24155273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazumdar S., Das K.M. Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am. J. Gastroenterol. 1992;87:176–181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1370872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe T., Kubota Y., Muto T. Substance P containing nerve fibers in rectal mucosa of ulcerative colitis. Dis. Colon. Rectum. 1997;40:718–725. doi: 10.1007/BF02140903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02140903</ArticleId>
            <ArticleId IdType="pubmed">9194468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koon H.W., Pothoulakis C. Immunomodulatory properties of substance P: The gastrointestinal system as a model. Ann. N. Y. Acad. Sci. 2006;1088:23–40. doi: 10.1196/annals.1366.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1196/annals.1366.024</ArticleId>
            <ArticleId IdType="pubmed">17192554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lysy J., Karmeli F., Sestieri M., Yatzkan Y., Goldin E. Decreased substance P content in the rectal mucosa of diabetics with diarrhea and constipation. Metabolism. 1997;46:730–734. doi: 10.1016/S0026-0495(97)90114-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0026-0495(97)90114-1</ArticleId>
            <ArticleId IdType="pubmed">9225823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel M., Valaiyaduppu Subas S., Ghani M.R., Busa V., Dardeir A., Marudhai S., Cancarevic I. Role of Substance P in the Pathophysiology of Inflammatory Bowel Disease and Its Correlation with the Degree of Inflammation. Cureus. 2020;12:e11027. doi: 10.7759/cureus.11027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7759/cureus.11027</ArticleId>
            <ArticleId IdType="pmc">PMC7671294</ArticleId>
            <ArticleId IdType="pubmed">33214955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonioli L., D’Antongiovanni V., Pellegrini C., Fornai M., Benvenuti L., di Carlo A., van den Wijngaard R., Caputi V., Cerantola S., Giron M.C., et al.  Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia. FASEB J. 2020;34:5512–5524. doi: 10.1096/fj.201901844R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.201901844R</ArticleId>
            <ArticleId IdType="pubmed">32086846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medhurst S.J., Collins S.D., Billinton A., Bingham S., Dalziel R.G., Brass A., Roberts J.C., Medhurst A.D., Chessell I.P. Novel histamine H3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain. Pain. 2008;138:61–69. doi: 10.1016/j.pain.2007.11.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2007.11.006</ArticleId>
            <ArticleId IdType="pubmed">18164820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medhurst A.D., Briggs M.A., Bruton G., Calver A.R., Chessell I., Crook B., Davis J.B., Davis R.P., Foley A.G., Heslop T., et al.  Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats. Biochem. Pharmacol. 2007;73:1182–1194. doi: 10.1016/j.bcp.2007.01.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2007.01.007</ArticleId>
            <ArticleId IdType="pubmed">17276409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh G.C., Honore P., Pai M., Wensink E.J., Chandran P., Salyers A.K., Wetter J.M., Zhao C., Liu H., Decker M.W., et al.  Antinociceptive effects of histamine H3 receptor antagonist in the preclinical models of pain in rats and the involvement of central noradrenergic systems. Brain Res. 2010;1354:74–84. doi: 10.1016/j.brainres.2010.07.083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2010.07.083</ArticleId>
            <ArticleId IdType="pubmed">20682302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teodoro F.C., Tronco Junior M.F., Zampronio A.R., Martini A.C., Rae G.A., Chichorro J.G. Peripheral substance P and neurokinin-1 receptors have a role in inflammatory and neuropathic orofacial pain models. Neuropeptides. 2013;47:199–206. doi: 10.1016/j.npep.2012.10.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.npep.2012.10.005</ArticleId>
            <ArticleId IdType="pubmed">23177733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizuta Y., Takahashi T., Owyang C. Nitrergic regulation of colonic transit in rats. Am. J. Physiol. 1999;277:G275–G279. doi: 10.1152/ajpgi.1999.277.2.G275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpgi.1999.277.2.G275</ArticleId>
            <ArticleId IdType="pubmed">10444440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chandrasekharan B., Anitha M., Blatt R., Shahnavaz N., Kooby D., Staley C., Mwangi S., Jones D.P., Sitaraman S.V., Srinivasan S. Colonic motor dysfunction in human diabetes is associated with enteric neuronal loss and increased oxidative stress. Neurogastroenterol. Motil. 2011;23:131–138. doi: 10.1111/j.1365-2982.2010.01611.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2982.2010.01611.x</ArticleId>
            <ArticleId IdType="pmc">PMC3020997</ArticleId>
            <ArticleId IdType="pubmed">20939847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cellek S., Foxwell N.A., Moncada S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes. 2003;52:2353–2362. doi: 10.2337/diabetes.52.9.2353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diabetes.52.9.2353</ArticleId>
            <ArticleId IdType="pubmed">12941776</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
